SEC Form 4 · accession 0001140361-17-038567
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul J Hastings
Officer — Chairman & CEO
Period of report
Oct 10, 2017
Accepted (ET)
Oct 12, 2017 · 6:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Oct 10, 2017 | S | 52 | $4.2611 | D | 77,534 | D | |
| Common StockF2 | Oct 10, 2017 | S | 1,346 | $4.2418 | D | 76,188 | D | |
| Common StockF3 | holding | — | — | — | 324,840 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit ("RSU") award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes.
- F2Includes 55,500 RSUs. The Reporting Person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof.
- F3The shares are held by Paul J. Hastings & Steve N. De Jong, Trustors and/or TTEES, The Hastings-De Jong Lv Tr DTD May 1, 2012.